ArticleScientific reports2020
Prevalence of atrophic gastritis in southwest China and predictive strength of serum gastrin-17: A cross-sectional study (SIGES).
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 44 citations in OpenAlex.
- N-acetylcysteine nano-spray versus conventional treatment in the management of radiotherapy-induced oral mucositis in oral cancer patients: a randomized clinical trial.BMC oral health · 2026Trial
- Hepatitis B Virus,Journal of clinical medicine · 2026Article
- Differential impacts of Helicobacter pylori antibody typing on gastric secretory function: a cross-sectional study based on serum biomarkers.BMC gastroenterology · 2026Observational
- The impact of washed microbiota transplantation on serum gastric function markers: pepsinogen I, pepsinogen II, and Gastrin-17.Frontiers in nutrition · 2026Article
- Serology and magnetically controlled capsule gastroscopy for opportunistic screening of high-risk events in gastric cancer development: a cross-sectional study.Frontiers in medicine · 2026Article
- An Opportunistic Screening Strategy for Gastric Cancer Based on Questionnaire and Sequential Serology: A Hospital-Based Cross-Sectional Study (SIGES).Journal of clinical medicine · 2025Article
- The potential value of serum pepsinogen and gastrin-17 for the diagnosis of chronic atrophic gastritis at different stages of severity: a clinical diagnostic study.BMC gastroenterology · 2025Article
- A novel nomogram for predicting the morbidity of chronic atrophic gastritis based on serum CXCL5 levels.BMC cancer · 2025Article
- Global progress and future prospects of early gastric cancer screening.Journal of Cancer · 2024Review
- Analysis of gastrin-17 and its related influencing factors in physical examination results.Immunity, inflammation and disease · 2023Article
- Crosstalk between3 Biotech · 2023Review
- Article
- The correlation of Th22 and regulatory T cells with Helicobacter pylori infection in patients with chronic gastritis.Immunity, inflammation and disease · 2023Article
- Potential Non-invasive Biomarkers of Helicobacter pylori-Associated Gastric Cancer.Journal of gastrointestinal cancer · 2022Review
- Microbial Proteins in Stomach Biopsies Associated with Gastritis, Ulcer, and Gastric Cancer.Molecules (Basel, Switzerland) · 2022Article
- Combination of Serum Test and Questionnaire in Early Gastric Cancer Screening.Iranian journal of public health · 2022Article
- Clinical Benefit and Cost Effectiveness of Risk-Stratified Gastric Cancer Screening Strategies in China: A Modeling Study.PharmacoEconomics · 2022Article
- Diagnostic performances of pepsinogens and gastrin-17 for atrophic gastritis and gastric cancer in Mongolian subjects.PloS one · 2022Article
- Benefit-to-harm ratio and cost-effectiveness of government-recommended gastric cancer screening in China: A modeling study.Frontiers in public health · 2022Article
- Development and Validation of Nomograms to Predict Operative Link for Gastritis Assessment Any-Stage and Stages III-IV in the Chinese High-Risk Gastric Cancer Population.Frontiers in medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A hospital-based cross-sectional study in SIGES project was conducted during 2016.5-2017.5 in West China Hospital. It was aimed to observe the prevalence of atrophic gastritis (AG) in southwest China, and assess the diagnostic strength of serum gastrin-17 (G-17) in predicting AG in Chinese population. Asymptomatic healthy controls from health check-up, cancer-free patients with unspecific upper gastrointestinal symptoms, and histologically proven gastric cancer patients were eligible, if serum pepsinogen-I (PG-I), PG-II, and G-17 were detected. AG status was classified by the accredited cutoffs of PG-I (<70 ug/L) and PG-I/II ratio (<3). Totally, healthy controls (n = 9,425), symptomatic patients (n = 671) and gastric cancer patients (n = 305) were simultaneously observed, in which the prevalence of AG in southwest China were estimated as 15.9/1,000, 28.3/1,000, and 55.7/1,000 persons, respectively. The age-specific prevalence of AG in healthy controls showed a significantly uphill trend (p for trend <0.001). Higher level of serum G-17 was significantly associated with increased risk of AG in healthy population (15-30 pmol/L, aOR = 20.67, 95% CI 9.17-46.55; >30 pmol/L, aOR = 314.41, 95% CI 166.10-595.12). Throughout the progression of stomach diseases, the diagnostic strength of serum G-17 for AG showed a downhill trend across more advanced situations. In despite of that, serum G-17 displayed a good performance in predicting AG in the entire cross-sectional population (AUC = 0.92, 95% CI 0.89-0.94; SEN = 85.5%; SPE = 93.2%; LR+ = 12.55; LR- = 0.11). Population in southwest China had intermediate prevalence of AG, while the prevalence was increased over age or disease progression. High level of serum G-17 might be a reliable non-invasive measurement to predict AG in southwest Chinese population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.